These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Health workers have long relied on Body Mass Index as a way to measure whether people are within a healthy weight range. Now, a collection of top researchers have made the case for a new way to ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

South Korea's trade minister Yeo Han-koo will visit the United States from June 22 to 27, the trade ministry said on Saturday ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Get ahead of Wall ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...